| MeSH term | MeSH ID | Detail |
|---|---|---|
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morrissey PE | Prope tolerance: is it the end or the means? | 2009 | Transplantation | pmid:19502973 |
| Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
| Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
| Prókai à et al. | Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. | 2016 | Transplantation | pmid:26502369 |
| Egawa H et al. | FK506 conversion therapy in pediatric liver transplantation. | 1994 | Transplantation | pmid:7513911 |
| Cvetkovic M et al. | The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. | 1994 | Transplantation | pmid:7513912 |
| Yang CW et al. | Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. | 2001 | Transplantation | pmid:11740384 |
| Hodge G et al. | Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. | 2010 | Transplantation | pmid:20559033 |
| Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
| Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
| Firdaous I et al. | Pediatric intravenous FK506--how much are we really infusing? | 1994 | Transplantation | pmid:7517079 |
| Cao W et al. | Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. | 1995 | Transplantation | pmid:7532879 |
| Murase N et al. | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. | 1990 | Transplantation | pmid:1696405 |
| Soccal PM et al. | Improvement of drug-induced chronic renal failure in lung transplantation. | 1999 | Transplantation | pmid:10428288 |
| Lee CM et al. | Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. | 1997 | Transplantation | pmid:9371670 |
| Migita K et al. | FK506 potentiates steroid-induced T-cell apoptosis. | 1997 | Transplantation | pmid:9371682 |
| Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
| Hricik DE et al. | Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2007 | Transplantation | pmid:17297401 |
| Fabrega AJ et al. | Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. | 1993 | Transplantation | pmid:7506458 |
| Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
| Sharif A et al. | Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. | 2010 | Transplantation | pmid:20145524 |
| Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
| Abu-Qaoud MS et al. | Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. | 2012 | Transplantation | pmid:23044666 |
| Woodward RS et al. | Renal graft survival and calcineurin inhibitor. | 2005 | Transplantation | pmid:16177637 |
| Merkle M et al. | The effect of sevelamer on tacrolimus target levels. | 2005 | Transplantation | pmid:16177649 |
| Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
| Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
| Demmers MW et al. | Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. | 2014 | Transplantation | pmid:24157471 |
| Aw MM et al. | Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 | Transplantation | pmid:11544444 |
| Terakura M et al. | Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. | 1998 | Transplantation | pmid:9721804 |
| Kai N et al. | Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. | 1993 | Transplantation | pmid:7682740 |
| Glicklich D et al. | Chronic renal allograft rejection: no response to mycophenolate mofetil. | 1998 | Transplantation | pmid:9721811 |
| Jacobson PA et al. | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. | 2011 | Transplantation | pmid:21206424 |
| Nolan TJ and Schad GA | Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. | 1996 | Transplantation | pmid:8878405 |
| Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
| Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
| Klein A et al. | Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. | 2009 | Transplantation | pmid:19300186 |
| Mikhalski D et al. | Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. | 2008 | Transplantation | pmid:18401260 |
| Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
| Mazariegos GV et al. | Weaning of immunosuppression in liver transplant recipients. | 1997 | Transplantation | pmid:9020325 |
| Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
| Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
| Krähenbühl S et al. | Serious interaction between mibefradil and tacrolimus. | 1998 | Transplantation | pmid:9808502 |
| Lerut J et al. | Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. | 2005 | Transplantation | pmid:16314784 |
| Letavernier E et al. | Proteinuria following a switch from calcineurin inhibitors to sirolimus. | 2005 | Transplantation | pmid:16314786 |
| Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
| Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
| Wai LE et al. | Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. | 2008 | Transplantation | pmid:18192925 |
| Jordan ML et al. | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. | 1994 | Transplantation | pmid:7512293 |
| Kashu Y et al. | The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. | 1996 | Transplantation | pmid:8633382 |